Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Maze TherapeuticsMAZE | Open-market sale10b5-1 plan | 06/22–06/23 | 06/24 | 27,858 sh3 trades | $26.04avg. | $725,501.25 | −8.0% | |
Maze TherapeuticsMAZE | Open-market sale10b5-1 plan | 06/01 | 06/03 | 6,643 sh2 trades | $26.20avg. | $174,068.72 | −19.2% | |
Maze TherapeuticsMAZE | Open-market sale10b5-1 plan | 06/01 | 06/03 | 14,853 sh2 trades | $25.66avg. | $381,055.21 | −100.0% | |
Atul DandekarCsbo | Maze TherapeuticsMAZE | Open-market sale10b5-1 plan | 05/29 | 06/02 | 7,500 sh | $26.34 | $197,550 | −23.2% |
Maze TherapeuticsMAZE | Open-market sale10b5-1 plan | 05/22–05/26 | 05/27 | 32,564 sh3 trades | $26.02avg. | $847,175.64 | −8.5% | |
Maze TherapeuticsMAZE | Open-market sale10b5-1 plan | 05/15 | 05/18 | 1,938 sh2 trades | $26.00avg. | $50,388 | −5.9% | |
Harold BernsteinPresident, R&D & CMO | Maze TherapeuticsMAZE | Open-market sale10b5-1 plan | 05/14 | 05/18 | 15,000 sh | $26.22 | $393,300 | −100.0% |
Atul DandekarCsbo | Maze TherapeuticsMAZE | Open-market sale10b5-1 plan | 04/29 | 05/01 | 7,500 sh | $25.37 | $190,275 | −41.7% |
Maze TherapeuticsMAZE | Open-market sale10b5-1 plan | 04/01 | 04/02 | 15,000 sh3 trades | $29.46avg. | $441,894.36 | −100.0% | |
Maze TherapeuticsMAZE | Open-market sale10b5-1 plan | 04/01 | 04/02 | 2,500 sh2 trades | $29.44avg. | $73,606 | −16.2% | |
Maze TherapeuticsMAZE | Open-market sale10b5-1 plan | 03/30 | 04/01 | 7,500 sh2 trades | $29.34avg. | $220,050.4 | −41.7% | |
Maze TherapeuticsMAZE | Open-market sale10b5-1 plan | 03/20 | 03/20 | 15,000 sh3 trades | $49.10avg. | $736,430.48 | −100.0% | |
Maze TherapeuticsMAZE | Open-market sale10b5-1 plan | 03/10 | 03/12 | 30,000 sh2 trades | $50.46avg. | $1,513,698.36 | −100.0% | |
Maze TherapeuticsMAZE | Open-market sale10b5-1 plan | 03/02 | 03/03 | 5,000 sh2 trades | $45.20avg. | $226,011 | −27.8% | |
Maze TherapeuticsMAZE | Open-market sale10b5-1 plan | 02/27 | 03/03 | 7,500 sh2 trades | $45.43avg. | $340,693.99 | −41.7% | |
Maze TherapeuticsMAZE | Open-market sale10b5-1 plan | 02/02 | 02/04 | 15,000 sh4 trades | $46.02avg. | $690,325.28 | −100.0% | |
Maze TherapeuticsMAZE | Open-market sale10b5-1 plan | 02/02 | 02/04 | 5,000 sh3 trades | $46.04avg. | $230,215.6 | −27.8% | |
Maze TherapeuticsMAZE | Open-market sale10b5-1 plan | 01/29 | 02/02 | 7,500 sh3 trades | $44.26avg. | $331,984 | −41.7% | |
Amy BachrodtSVP, Finance | Maze TherapeuticsMAZE | Open-market sale10b5-1 plan | 01/22 | 01/26 | 5,000 sh | $45.52 | $227,600 | −27.8% |
Harold BernsteinPresident, R&D & CMO | Maze TherapeuticsMAZE | Open-market sale10b5-1 plan | 01/07 | 01/09 | 25,156 sh | $40.20 | $1,011,271.2 | −100.0% |